| Name | Title | Contact Details |
|---|
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.
The Warner Babcock Institute for Green Chemistry is dedicated to the development of non toxic, environmentally benign and sustainable technological solutions for society. Focused on the practical application of Green Chemistry, we assist our industry partners in the development of sustainable technologies, products, and processes at the molecular level. Our emphasis is on the practical application of Green Chemistry concepts to drive cost savings and minimize time to market. The Warner Babcock Institute for Green Chemistry was founded in 2007 by Dr. John C. Warner, one of the founders of the field and co-author of seminal book Green Chemistry: Theory and Practice, which first defined the Twelve Principles of Green Chemistry.
Why we`re excited: The mission for Payformance Solutions is simple. We aim to be a catalyst for payment transformation in the healthcare industry. Our proprietary software solutions allow payers and providers to focus on what really matters: providing patients with access to care that yields the best health outcomes, at the lowest costs. The healthcare industry is complex and fragmented. Payers and providers are faced with a lack of transparency and conflicting financial goals that fail to consider the health outcomes of patients. Payformance offers data-driven, turnkey software solutions that provide payers and providers with the technical tools and resources needed to design, evaluate, build, measure, and negotiate value-based reimbursement contracts — as a neutral third party. Our holistic solutions allow payers and providers to collaborate in an ecosystem that aligns financial goals with patient outcomes. Not to boast, but a little bit about us: Payformance Solutions is a health-tech company dedicated to advancing payment transformation in the healthcare industry. We are a wholly owned subsidiary of Altarum Institute, a nonprofit systems research and consulting organization that has been servicing government and private sector clients since 1946. Altarum Institute, as a non-profit, ensures that the public interest is always preeminent in client work. Our dedication to social responsibility is evident in all that we do, serving the public good with integrity and enabling others to do the same. Altarum develops and promotes best practices in the application of information technology to health and health care. Applying systems research principles and analytic objectivity, we work to increase access to health information; improve the organization and usability of health information; and develop new knowledge from health information.
ianacare is the best way for family caregivers to get the help and practical support they need (meals, rides, respite care, child care, pet care, house errands) from the people in their social circles, community, and co-workers who want to help. Get St...
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.